GlassScriptPhysician profile
David Lee Hopper
NPI 1487298105
$1,539.10
in general payments reported to CMS, 2019-2025
18 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.81 · 2022: $235 · 2023: $231 · 2024: $201 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.31 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $359.76 | 2021-2025 | Breztri, Fasenra, Farxiga |
| Genzyme Corporation | $261.95 | 2024-2025 | |
| Insmed, INC. | $175.56 | 2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.06 | 2025 | Ofev, Jardiance, Jascayd |
| Regeneron Healthcare Solutions, INC. | $93.11 | 2024 | Dupixent |
| Glaxosmithkline, LLC. | $81.90 | 2022-2025 | Nucala, Trelegy Ellipta |
| Baxter Healthcare | $75.64 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $66.73 | 2022-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $44.60 | 2023-2024 | Aralast, Glassia |
| Harmony Biosciences LLC | $39.63 | 2025 | |
| Amgen INC. | $39.09 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $33.24 | 2025 | Yupelri |
| Dexcom, INC. | $21.79 | 2022 | |
| Merck Sharp & Dohme LLC | $20.16 | 2025 | Capvaxive |
| Si-Bone, INC. | $18.27 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $15.56 | 2022 | |
| Boston Scientific Corporation | $13.97 | 2023 | Wavewriter Alpha Prime 16 |
| Bioventus LLC | $13.08 | 2024 | Gelsyn-3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.